← All trials
NCT01714414
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2012
- Primary completion
- Jun 1, 2014
- Completion date
- Feb 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Ludwig Maximilians UniversityLead sponsor
- Ludwig Maximilians UniversityStudy director
- National Institute for Medical Research, TanzaniaCollaborator
- Bernhard Nocht Institute for Tropical MedicineCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- German Federal Ministry of Education and ResearchCollaborator
- Treichville Academic hospital centerCollaborator
- Kumasi Centre for Collaborative ResearchCollaborator
- STADA Arzneimittel AGCollaborator
- Government of FranceCollaborator
- Chiracon GmbHCollaborator
- Ludwig Maximilians UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.